Quality compounders
Profit compounding above 15% a year for five years, under 30 times earnings, interest costs up less than 5%, financials excluded.
Three legs, each closing a hatch the others leave open. Five years of trailing-twelve-month profit growth is the compounding test: one good year against a soft base cannot carry a five-year rate, and a company that grew through a full cycle is a different animal from one that caught a single upswing. The P/E ceiling is the price test, because compounding the market has already paid for is not an opportunity. The interest leg watches borrowing every quarter. The balance sheet, and with it `debt_to_equity`, arrives only with the half-year and annual filings, while the interest bill moves with each result. Flat interest beside compounding profit is growth funded from earnings; a jump is the tell that it was funded with borrowing. Lenders are excluded for exactly that reason, since for a bank the interest paid is a cost of goods and rises with a healthy loan book. Coverage is the real limit. The results backfill starts in 2018, so roughly half of covered names can answer a five-year question at all and the rest are NULL, which never matches. Widen it with `profit_cagr_3y`, lengthen it with `profit_cagr_7y`, or add `profit_growth_yoy > 15` to insist the latest quarter is still delivering.
More fundamentals:Promoters buyingPromoters sellingPromoters buying in the open marketSeveral insiders buyingHigh promoter holding in an uptrend
Price and delivery data from the eod2 dataset: National Stock Exchange of India end-of-day files, split- and bonus-adjusted, updated after each close. Not affiliated with or endorsed by NSE. PatternsRadar is a research tool. Nothing here is investment advice or a recommendation to buy or sell anything.